Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028

뉴스 본문을 불러오고 있어요.

Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028 | 웨이프 WAPE

Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028

기사 요약

관련 종목

댓글 —